Latest Regulatory Compliance News

Australian Dairy Nutritionals reported a 152% surge in nutritional powder sales despite regulatory hurdles in Vietnam, while expanding its Future brand footprint across China.

Chilwa Minerals has finalised the last tranche of its $8 million private placement, bolstered by insider participation, and is advancing plans for a Nasdaq dual listing in the first half of 2026.

The Australian Competition and Consumer Commission has advanced its review of Ampol’s acquisition of EG Australia to a more detailed Phase 2 assessment, signalling potential competition concerns. Ampol remains optimistic about completing the deal by mid-2026 despite the regulatory scrutiny.

Galileo Mining Ltd has responded to an ASX price and volume query, confirming no undisclosed material information exists to explain recent trading activity. The company attributes the surge to positive market sentiment around its Norseman Project and lithium joint venture with Mineral Resources.

Eagle Mountain Mining has launched a Placement Options Offer for 61.3 million options attaching to recent placement shares, potentially raising $1.23 million upon exercise. The offer supports ongoing exploration and strategic initiatives in Arizona copper projects.

29Metals reported a strong December quarter with increased copper and zinc production at Golden Grove, cost efficiencies, and steady progress on key projects, while Capricorn Copper remains suspended pending regulatory approvals.

Phoslock Environmental Technologies has amended its December 2025 quarterly report to correct funding data and withdraw its sales outlook, while reporting improved cash flow and resuming factory operations.

DXN Limited has signed a strategic MOU with Super Sistem Indonesia to form a joint venture targeting Indonesia’s rapidly expanding digital infrastructure market, aiming for US$7 million in revenue over three years.

Mitchell Asset Management challenges Identitii Limited’s recent rights issue, alleging it could unfairly boost Beauvais Capital’s stake close to 50%, sparking a potential showdown at the Takeovers Panel.

Neuren Pharmaceuticals has affirmed the material impact of Acadia’s projection that DAYBUE global net sales could reach approximately US$700 million by 2028, underpinning its royalty revenue outlook.

Phoslock Environmental Technologies has reversed its cashflow deficits with a quarterly surplus, resumed factory operations after a long pause, and is gearing up for significant sales growth in 2026.

Tetratherix has inked a global exclusive distribution agreement with healthcare giant Henry Schein, paving the way for its first bone regeneration product, Tegenix, to enter major markets in 2026. Concurrently, the company has begun building an advanced manufacturing facility to meet expected global demand.